Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia
Recruiting
Phase 3
Interventional Study
Ventilator-associated Pneumonia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 80 (estimated)
- Sponsor
- University Hospital, Toulouse · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
inclusion criteria
* patients with ventilator associated-pneumonia to Pseudomonas aeruginosa
* patients hospitalized in intensive care units
* Pseudomonas aeruginosa susceptible to ceftolozane-tazobactam
* Simplified Acute Physiological Score II (SAPS II () \> 20
* Expected duration of survival \> …
Contacts